Issue
Date Log
Copyright (c) 2026 Daifallah Dahwi Abdulrhman, Nouri Marzouq Mutlaq Alotaibi, Rahaf Abddulrahman Almutairi, Faten Moeid Almutairi, Seham Khalaf Rasheed Almutiri, Ayda Saeed Almotiri, Anbar Omar Amer Almutiri, Maeetm Abdurhman Alhafi, Huda Muhammad Metleaa Al Mutairi, Nayafah Miedid Mishean Almutayri

This work is licensed under a Creative Commons Attribution 4.0 International License.
Nursing Assessment and Management of La Crosse Encephalitis in Pediatric Patients: Clinical Manifestations and Neurological Outcomes
Corresponding Author(s) : Daifallah Dahwi Abdulrhman
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: La Crosse encephalitis is a mosquito-borne viral infection caused by La Crosse virus, an orthobunyavirus belonging to the California serogroup. The disease primarily affects children and represents an important cause of arboviral encephalitis in the United States. Although most infections remain asymptomatic or produce mild febrile illness, neuroinvasive disease can cause seizures, encephalopathy, cerebral edema, and long-term neurological complications.
Aim: This review examines the etiology, epidemiology, pathophysiology, histopathological characteristics, clinical manifestations, diagnostic evaluation, treatment, prognosis, and complications of La Crosse encephalitis, with emphasis on clinical assessment and nursing management.
Methods: A narrative review approach was used to examine the available clinical and scientific literature addressing La Crosse virus infection. Relevant evidence concerning viral transmission, disease mechanisms, clinical presentation, laboratory diagnosis, neuroimaging, supportive treatment, and short- and long-term outcomes was synthesized.
Results: La Crosse virus is transmitted primarily through infected Aedes mosquitoes, with vertical transmission contributing to viral persistence in mosquito populations. The incubation period ranges from 5 to 15 days. Symptomatic patients commonly develop fever, headache, vomiting, and lethargy, while severe cases may present with seizures, altered consciousness, and cerebral edema. Diagnosis primarily relies on virus-specific IgM antibody detection in serum or cerebrospinal fluid, supported by neutralizing antibody testing. No established specific antiviral treatment is available. Management focuses on supportive care, seizure control, fluid and electrolyte management, and respiratory support when required. Although mortality is relatively low, some survivors experience recurrent seizures, cognitive impairment, behavioral changes, and developmental difficulties.
Conclusion: Early recognition, appropriate diagnostic evaluation, and supportive management are essential to reduce complications and improve outcomes. Long-term neurological and developmental follow-up remains important, particularly in affected children.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1. Thompson Wh, Kalfayan B, Anslow Ro. Isolation Of California Encephalitis Group Virus From A Fatal Human Illness. Am J Epidemiol. 1965 Mar;81:245-53.
- 2. Byrd BD. La Crosse Encephalitis: A Persistent Arboviral Threat in North Carolina. N C Med J. 2016 Sep-Oct;77(5):330-3.
- 3. Goldman T, Hamer DH. Current Status of La Crosse Virus in North America and Potential for Future Spread. Am J Trop Med Hyg. 2024 May 01;110(5):850-855.
- 4. Teleron AL, Rose BK, Williams DM, Kemper SE, McJunkin JE. La Crosse Encephalitis: An Adult Case Series. Am J Med. 2016 Aug;129(8):881-4.
- 5. Woodring J, Chandler LJ, Oray CT, McGaw MM, Blair CD, Beaty BJ. Short report: Diapause, transovarial transmission, and filial infection rates in geographic strains of La Crosse virus-infected Aedes triseriatus. Am J Trop Med Hyg. 1998 May;58(5):587-8.
- 6. Thompson WH, Beaty BJ. Venereal transmission of La Crosse virus from male to female Aedes triseriatus. Am J Trop Med Hyg. 1978 Jan;27(1 Pt 1):187-96.
- 7. Darby CS, Featherston KM, Lin J, Franz AWE. Detection of La Crosse Virus In Situ and in Individual Progeny to Assess the Vertical Transmission Potential in Aedes albopictus and Aedes aegypti. Insects. 2023 Jul 03;14(7)
- 8. Day CA, Byrd BD, Trout Fryxell RT. La Crosse virus neuroinvasive disease: the kids are not alright. J Med Entomol. 2023 Nov 14;60(6):1165-1182.
- 9. Vahey GM, Lindsey NP, Staples JE, Hills SL. La Crosse Virus Disease in the United States, 2003-2019. Am J Trop Med Hyg. 2021 Jul 19;105(3):807-812.
- 10. Jones TF, Erwin PC, Craig AS, Baker P, Touhey KE, Patterson LE, Schaffner W. Serological survey and active surveillance for La Crosse virus infections among children in Tennessee. Clin Infect Dis. 2000 Nov;31(5):1284-7.
- 11. Faw LR, Riley J, Eastwood G. La Crosse Virus Circulation in Virginia, Assessed via Serosurveillance in Wildlife Species. Infect Dis Rep. 2023 Jun 30;15(4):360-369.
- 12. Hacker JK, Volkman LE, Hardy JL. Requirement for the G1 protein of California encephalitis virus in infection in vitro and in vivo. Virology. 1995 Feb 01;206(2):945-53.
- 13. McJunkin JE, Khan RR, Tsai TF. California-La Crosse encephalitis. Infect Dis Clin North Am. 1998 Mar;12(1):83-93.
- 14. McJunkin JE, Khan R, de los Reyes EC, Parsons DL, Minnich LL, Ashley RG, Tsai TF. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics. 1997 Feb;99(2):261-7.
- 15. Murphree R, Dunn JR, Schaffner W, Jones TF. La Crosse encephalitis surveillance using single versus paired serologic testing. Zoonoses Public Health. 2012 May;59(3):181-3.
- 16. McJunkin JE, de los Reyes EC, Irazuzta JE, Caceres MJ, Khan RR, Minnich LL, Fu KD, Lovett GD, Tsai T, Thompson A. La Crosse encephalitis in children. N Engl J Med. 2001 Mar 15;344(11):801-7.
- 17. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1993 Mar;37(3):532-9.
- 18. Hosoya M, Shigeta S, Mori S, Tomoda A, Shiraishi S, Miike T, Suzuki H. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2001 Mar;45(3):943-5.
- 19. McJunkin JE, Nahata MC, De Los Reyes EC, Hunt WG, Caceres M, Khan RR, Chebib MG, Taravath S, Minnich LL, Carr R, Welch CA, Whitley RJ. Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr Infect Dis J. 2011 Oct;30(10):860-5.
- 20. Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother. 1989 Nov;33(11):2009-11.
- 21. Haddow AD, Haddow AD. The use of oral ribavirin in the management of La Crosse viral infections. Med Hypotheses. 2009 Feb;72(2):190-2.
- 22. Balkhy HH, Schreiber JR. Severe La Crosse encephalitis with significant neurologic sequelae. Pediatr Infect Dis J. 2000 Jan;19(1):77-80.
References
1. Thompson Wh, Kalfayan B, Anslow Ro. Isolation Of California Encephalitis Group Virus From A Fatal Human Illness. Am J Epidemiol. 1965 Mar;81:245-53.
2. Byrd BD. La Crosse Encephalitis: A Persistent Arboviral Threat in North Carolina. N C Med J. 2016 Sep-Oct;77(5):330-3.
3. Goldman T, Hamer DH. Current Status of La Crosse Virus in North America and Potential for Future Spread. Am J Trop Med Hyg. 2024 May 01;110(5):850-855.
4. Teleron AL, Rose BK, Williams DM, Kemper SE, McJunkin JE. La Crosse Encephalitis: An Adult Case Series. Am J Med. 2016 Aug;129(8):881-4.
5. Woodring J, Chandler LJ, Oray CT, McGaw MM, Blair CD, Beaty BJ. Short report: Diapause, transovarial transmission, and filial infection rates in geographic strains of La Crosse virus-infected Aedes triseriatus. Am J Trop Med Hyg. 1998 May;58(5):587-8.
6. Thompson WH, Beaty BJ. Venereal transmission of La Crosse virus from male to female Aedes triseriatus. Am J Trop Med Hyg. 1978 Jan;27(1 Pt 1):187-96.
7. Darby CS, Featherston KM, Lin J, Franz AWE. Detection of La Crosse Virus In Situ and in Individual Progeny to Assess the Vertical Transmission Potential in Aedes albopictus and Aedes aegypti. Insects. 2023 Jul 03;14(7)
8. Day CA, Byrd BD, Trout Fryxell RT. La Crosse virus neuroinvasive disease: the kids are not alright. J Med Entomol. 2023 Nov 14;60(6):1165-1182.
9. Vahey GM, Lindsey NP, Staples JE, Hills SL. La Crosse Virus Disease in the United States, 2003-2019. Am J Trop Med Hyg. 2021 Jul 19;105(3):807-812.
10. Jones TF, Erwin PC, Craig AS, Baker P, Touhey KE, Patterson LE, Schaffner W. Serological survey and active surveillance for La Crosse virus infections among children in Tennessee. Clin Infect Dis. 2000 Nov;31(5):1284-7.
11. Faw LR, Riley J, Eastwood G. La Crosse Virus Circulation in Virginia, Assessed via Serosurveillance in Wildlife Species. Infect Dis Rep. 2023 Jun 30;15(4):360-369.
12. Hacker JK, Volkman LE, Hardy JL. Requirement for the G1 protein of California encephalitis virus in infection in vitro and in vivo. Virology. 1995 Feb 01;206(2):945-53.
13. McJunkin JE, Khan RR, Tsai TF. California-La Crosse encephalitis. Infect Dis Clin North Am. 1998 Mar;12(1):83-93.
14. McJunkin JE, Khan R, de los Reyes EC, Parsons DL, Minnich LL, Ashley RG, Tsai TF. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics. 1997 Feb;99(2):261-7.
15. Murphree R, Dunn JR, Schaffner W, Jones TF. La Crosse encephalitis surveillance using single versus paired serologic testing. Zoonoses Public Health. 2012 May;59(3):181-3.
16. McJunkin JE, de los Reyes EC, Irazuzta JE, Caceres MJ, Khan RR, Minnich LL, Fu KD, Lovett GD, Tsai T, Thompson A. La Crosse encephalitis in children. N Engl J Med. 2001 Mar 15;344(11):801-7.
17. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1993 Mar;37(3):532-9.
18. Hosoya M, Shigeta S, Mori S, Tomoda A, Shiraishi S, Miike T, Suzuki H. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2001 Mar;45(3):943-5.
19. McJunkin JE, Nahata MC, De Los Reyes EC, Hunt WG, Caceres M, Khan RR, Chebib MG, Taravath S, Minnich LL, Carr R, Welch CA, Whitley RJ. Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr Infect Dis J. 2011 Oct;30(10):860-5.
20. Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother. 1989 Nov;33(11):2009-11.
21. Haddow AD, Haddow AD. The use of oral ribavirin in the management of La Crosse viral infections. Med Hypotheses. 2009 Feb;72(2):190-2.
22. Balkhy HH, Schreiber JR. Severe La Crosse encephalitis with significant neurologic sequelae. Pediatr Infect Dis J. 2000 Jan;19(1):77-80.